ISSN 0973 - 9289
Neonatal ARV prophylaxis
Reepa Agrawal
A 32 years old HIV infected pregnant female (G2P2L1) presented at 36 weeks of pregnancy for deciding neonatal antiretroviral (ARV) prophylaxis. Her HIV viral load at 34 weeks of gestation was undetectable and she was on antiretroviral therapy (ART) consisting of tenofovir, lamivudine and dolutegravir. She has opted for an elective caesarean section delivery. She had previously been on nevirapine based regimen but had developed a rash due to same and so nevirapine was omitted from her ART regimen. Her first born child was given Nevirapine (NVP) for 6 weeks as ARV prophylaxis and replacement feeding. He was HIV uninfected on testing.

What should be the neonatal ARV prophylaxis for the coming newborn baby and why?
Hiv in Children

This website is with a purpose to create awareness about impact of HIV in children, to dispel the myths and misconceptions and to aid the clinicians to develop a clinical acumen for effective management of these children and the affected families.




St.Francis Road

Vile Parle(W),


E-Mail Address :

Copyright © 2001 - 2024 HIV In Children All Rights Reserved. All trademarks used are the properties of their respective owners.
Disclaimer: The information given by is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by HivInChildren of the quality or value of the said product or of claims made by its manufacturer.